| Ehiremen Martins Iyoha, MD | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Ehiremen Martins Iyoha |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 3 Years |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760065692 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 31640 (Minnesota) | Secondary |
| 207Y00000X | Otolaryngology | 71970 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic | 6507778255 | 4232 |
News Archive
Gilead Sciences, Inc. and CGI Pharmaceuticals, Inc., a privately-held, development-stage pharmaceutical company focused on small molecule chemistry and kinase biology, today announced the signing of a definitive agreement pursuant to which Gilead will acquire CGI. Under the terms of the agreement, Gilead will acquire CGI for up to $120 million, the majority as an upfront payment and the remaining based on clinical development progress, all of which will be financed through available cash on hand.
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from PALACE 3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain.
Celgene Corporation today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
University of Warwick researchers are to improve the lives of India's millions of psychosis sufferers.
› Verified 4 days ago
| Entity Name | Mayo Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
Gilead Sciences, Inc. and CGI Pharmaceuticals, Inc., a privately-held, development-stage pharmaceutical company focused on small molecule chemistry and kinase biology, today announced the signing of a definitive agreement pursuant to which Gilead will acquire CGI. Under the terms of the agreement, Gilead will acquire CGI for up to $120 million, the majority as an upfront payment and the remaining based on clinical development progress, all of which will be financed through available cash on hand.
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from PALACE 3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain.
Celgene Corporation today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
University of Warwick researchers are to improve the lives of India's millions of psychosis sufferers.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ehiremen Martins Iyoha, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Ehiremen Martins Iyoha, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
Gilead Sciences, Inc. and CGI Pharmaceuticals, Inc., a privately-held, development-stage pharmaceutical company focused on small molecule chemistry and kinase biology, today announced the signing of a definitive agreement pursuant to which Gilead will acquire CGI. Under the terms of the agreement, Gilead will acquire CGI for up to $120 million, the majority as an upfront payment and the remaining based on clinical development progress, all of which will be financed through available cash on hand.
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from PALACE 3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain.
Celgene Corporation today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
University of Warwick researchers are to improve the lives of India's millions of psychosis sufferers.
› Verified 4 days ago
Dr. Kendall Krystyna Tasche, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Charles Wayne Beatty, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jan L Kasperbauer, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Nicolas Ernest Maragos, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Laura J Orvidas, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Nicholas Reed Randall, MD Otolaryngology Medicare: May Accept Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Lazaro Rafael Peraza, MD Otolaryngology Medicare: May Accept Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |